A trial update for NCT05050084 was recorded on June 25, 2026, involving buserelin. The study is titled "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial."
This is a Phase 3 study. Its current status is listed as active, not recruiting. The trial evaluates two distinct treatment approaches based on gene risk score categorization in patients with unfavorable intermediate risk prostate cancer. One arm tests a less intense treatment strategy for those with a low gene risk score, while another arm tests a more intense treatment strategy for those with a higher gene risk score.
No results have been reported as part of this update. The status change reflects only that the trial is no longer recruiting new participants and remains active. No efficacy, safety, or outcome data are included in this update.
Readers can consult the compound overview for additional context on buserelin.